DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/0359c6/vertex_pharmaceuti) has announced the addition of the "Vertex Pharmaceuticals Inc.: PharmaVitae Profile" company profile to their offering.
This analysis examines the historical and forecast performance for Vertex in the prescription pharmaceutical sector. The profile encompasses key product analysis and forecasts, pipeline assessment, and evaluation of company strategy and financial performance over a 6-year period.
Features and Benefits:
- Gain insight into Vertex's strategic outlook across the next 6 years
- Analysis of strategically important company products, supported by patient-based forecasting and key opinion leader interviews
Highlights:
- Strategic evaluation of Vertex's outlook for the next six years. Assessment of key strengths, weaknesses, opportunities and threats and appraisal of the company's product portfolio, pipeline and commercial relationships.
Your Key Questions Answered:
- See how Vertex is set to emerge as a leading player in the global hepatitis C market via the launch of Incivek
- Assess the impact of the Incivek launch in the evolution of Vertex towards becoming a fully integrated biopharma player
- Read key opinion leaders' assessment of Incivek, supporting the view that it will emerge as the leading protease inhibitor for HCV therapy
- Learn how Vertex's commercial momentum will be maintained by the launch of a second new product, the developmental cystic fibrosis treatment VX-770
- View The patient-based forecasts for Incivek and VX-770
Key Topics Covered:
Executive Summary
- Company introduction
- Recent developments
- Corporate relationships
- Strategic overview
- Momentum enhanced by launch of VX-
- Strategic outlook
- SWOT analysis
About This Pharmavitae Report
- Chapter structure
- Sales and Product Analysis
- Financial Analysis
- Data sourcing
- Analyst consensus
Sales and Product Analysis
- Sales overview
- Product analysis
- Product sales
- Incivek (telaprevir)
- Key competitors
- Clinical trials
- Comparative Phase III trial results for boceprevir
- Commercial impact of telaprevir and boceprevir Phase III results
- Physician opinion
- Key product events
- VX-770 trials are ongoing, results filter through during
- VX-770's potential to become the first agent addressing CFTR dysfunction is creating excitement among CF specialists
Financial Analysis
- Financial performance overview
- Operating costs and profit analysis
Appendix
- Abbreviations
- Exchange rates
For more information visit http://www.researchandmarkets.com/research/0359c6/vertex_pharmaceuti
Source: Datamonitor